A new Danish alliance was formed last week to combat an escalating health crisis due to antibiotic-resistant bacteria (AMR).
The Novo Nordisk Foundation announced the launch of the Danish AMR Alliance .
Members of the alliance include Pfizer Denmark and Pharmadanmark, as well as 18 other Danish partners from business, associations and academia.
The collaboration aims to combat the rapidly-spreading phenomenon of AMR, which can turn simple injuries into major health risks.
Studies indicate that AMR will claim as many lives as cancer by the year 2050, emphasized Hans Jorn Kolmos, professor of Clinical Microbiology at the University of Southern Denmark and Odense University Hospital.
"Without effective intervention against AMR, we face a future where basic medical procedures become highly risky," said Kolmos in the press release.
The Danish AMR Alliance aims to unify global efforts to tackle this expanding threat.
"The challenge of antimicrobial resistance cannot be solved by one country alone and requires a global effort. Denmark can play an important role in this by establishing significant initiatives that can inspire other countries to follow," said Steffen Pierini Luders, senior vice president of the Novo Nordisk Foundation.
AMR was directly responsible for 1.2 million deaths worldwide in 2019, according to Global Research on Antimicrobial Resistance report published in The Lancet in 2022. The Novo Nordisk Foundation said that the situation is particularly dire in the Global South, where AMR's impact is disproportionately severe.